RxDoctor Payments Data

Nicol Montez

Family · Phoenix, AZNPI 1871016394

Payments from drug & device makers

$905in general payments, 2019–2025

Across 14 payments — averaging $64.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$295
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$232
  • AstraZeneca$204
  • Johnson & Johnson$84
  • Impulse Dynamics (USA) Inc.$39
  • Philips North America LLC$35
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$905100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$905 in reported general payments places this provider in the 65th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$76,187
Medicare patients
102
Services billed
740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban180$115,706
EntrestoSacubitril/Valsartan43$30,590
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$23,356
JardianceEmpagliflozin25$16,368
XareltoRivaroxaban20$11,293
Breo ElliptaFluticasone/Vilanterol12$8,091
JanuviaSitagliptin Phosphate11$6,320
LumiganBimatoprost14$5,176
Memantine Hcl100$4,552
Atorvastatin Calcium242$3,901
Tamsulosin Hcl139$3,542
Levothyroxine Sodium214$3,201
Sucralfate21$3,174
Pantoprazole Sodium119$2,864
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc28$2,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$84$11,29320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →